Selinexor
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., LtdSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
104 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dexasone City of Hope Medical Center | Phase 2/3 | BB |
Isocyclophosphamide University of California, Davis | Phase 3 | BB |
Axicabtagene Ciloleucel Zhujiang Hospital | Phase 3 | BB |
Cyclophosphamide Nathan Denlinger | Phase 3 | BB |
Etoposide University of California, Davis | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Selinexor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →